ReviewCureus2025
A Comprehensive Literature Review of the CDH1 Mutation and Its Role in Gastric Cancer.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular features of early- vs. late-onset gastric cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges.International journal of cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary diffuse gastric cancer (HDGC) is a significant genetic predisposition syndrome, primarily caused by germline mutations in the CDH1 gene, which encodes the E-cadherin protein - a critical component for cell adhesion and tissue integrity. Individuals with HDGC have an increased risk of developing diffuse-type gastric cancer, which is characterized by the infiltration of the stomach wall by poorly cohesive, single-cell carcinoma. This aggressive form of gastric cancer is challenging to detect at an early stage and is associated with a poor prognosis. The identification and understanding of the genetic basis of HDGC are crucial for improving early detection, risk assessment, and the development of targeted treatment strategies for this hereditary cancer syndrome. This review aims to provide a comprehensive overview of the genetic and molecular mechanisms underlying HDGC, with a focus on the role of CDH1 mutations. It discusses current diagnostic criteria, genetic testing strategies, and the implications of a positive CDH1 mutation for clinical management - including surveillance, prophylactic gastrectomy, and family counseling. Additionally, this review highlights recent advancements in understanding the impact of CDH1 loss on cellular pathways and the potential for novel therapeutic approaches targeting these molecular changes. By consolidating the existing knowledge and addressing current gaps, this review aims to support clinicians and researchers in enhancing the care and outcomes of individuals and families affected by HDGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.